6CM
ANIX icon

683 Capital Management’s Anixa Biosciences ANIX Stock Holding History

683 Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113,636
Closed -$355K – 239
2025
Q4 		$355K Buy
+113,636
New +$465K 0.02% 214

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

683 Capital Management's ANIX Position: Q1 2026 in Review

683 Capital Management sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 113,636 shares — an estimated $355K sold.

683 Capital Management first reported a position in ANIX in Q4 2025 and held it in 1 quarter. The position peaked at $355K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • 683 Capital Management reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • 683 Capital Management sold 113,636 Anixa Biosciences shares in Q1 2026, an estimated $355K.
  • 683 Capital Management first reported a position in Anixa Biosciences in Q4 2025 and held it in 1 quarter.
  • 683 Capital Management's Anixa Biosciences position peaked at $355K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.